PRQR
ProQR Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRQR
Proqr Therapeutics N.V.
A developer of RNA-based therapeutics that treat severe genetic disorders
Zernikedreef 9, 2333 CK Leiden, The Netherlands
--
ProQR Therapeutics N.V. is a limited liability company established in the Netherlands on February 21, 2012. The company is a biotechnology company dedicated to creating transformative RNA therapies to improve the lives of patients and families affected by diseases with high unmet medical needs. To achieve this goal, the company is advancing its proprietary Axiomer RNA editing platform technology. The Company's product candidates are designed to utilize adenosine deaminase for targeted RNA editing (" ADAR "), which the Company believes has the potential to become a new class of innovative drugs for a wide range of therapeutic areas.
Company Financials
EPS
PRQR has released its 2025 Q3 earnings. EPS was reported at -0.1, versus the expected -0.17, beating expectations. The chart below visualizes how PRQR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRQR has released its 2025 Q3 earnings report, with revenue of 3.42M, reflecting a YoY change of -22.90%, and net profit of -12.92M, showing a YoY change of -42.93%. The Sankey diagram below clearly presents PRQR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
